
AskBio’s AB-1005 GDNF Gene Therapy for Parkinson’s Receives FDA Fast Track, MHRA Innovation Passport
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company fully owned by Bayer AG, announced today that the FDA has granted Fast Track Designation for AB-1005, intended for moderate Parkinson’s disease. AB-1005 has also received the Innovation Passport…














